ATG-106

N/A

Report date: 2026/03/19 17:09:36

Base Information

Drug NameATG-106

Drug Alias NameCDH6 x CD3 T细胞衔接器ATG-106ATG106

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein +[4]

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsCadherin-6 modulators

TargetsT cell surface glycoprotein CD3Cadherin-6

Therapy Area/IndicationsOvarian NeoplasmsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesAntengene Corp Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAntengene Corp Ltd

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A